Variables | Mortality group (N = 6) | Survival group (N = 12) | P-value |
---|---|---|---|
Demographics | Â | Â | Â |
Age (X ± SD, years) | 53.8 ± 24.2 | 31.4 ± 19.4 | 0.050 |
Sex, male | 4 (66.7) | 6 (50.0) | 0.638 |
Hospitalization | Â | Â | Â |
Length of stay, (IQR, days) | 4 (66.7) | 10 (83.3) | 0.569 |
Transferring from another hospital | 1 (16.7) | 2 (16.7) | 1.000 |
Admission to ICU | 2 (33.3) | 4 (33.3) | 1.000 |
Prior hospitalization | 5 (83.3) | 8 (66.7) | 0.615 |
Comorbid conditions | Â | Â | 1.000 |
Diabetes mellitus | 1 (16.7) | 1 (8.3) | 1.000 |
Solid tumor | 1 (16.7) | 1 (8.3) | 1.000 |
Pneumonia | 5 (83.3) | 9 (75.0) | 1.000 |
Liver disease | 4 (66.7) | 5 (41.7) | 0.620 |
Gastritis | 2 (33.3) | 2 (16.7) | 0.569 |
Shock | 6 (100.0) | 2 (16.7) | 0.002* |
Diarrhea | 4 (66.7) | 9 (75.0) | 1.000 |
Invasive procedures | Â | Â | Â |
Central venous catheter | 4 (66.7) | 10 (83.3) | 0.569 |
Arterial catheter | 2 (33.3) | 2 (16.7) | 0.569 |
Endotracheal intubation | 2 (33.3) | 0 (0.0) | 0.098 |
Mechanical ventilation | 4 (66.7) | 6 (50.0) | 0.638 |
Urinary catheter | 2 (33.3) | 2 (16.7) | 0.569 |
Nasogastric tube | 3 (50.0) | 1 (8.3) | 0.083 |
HSCT | 0 (0.0) | 5 (41.7) | 0.114 |
Drug exposure | Â | Â | Â |
PPIs | 4 (66.7) | 11 (91.7) | 0.245 |
Glucocorticoid | 5 (83.3) | 8 (66.7) | 0.615 |
Cephalosporins | 1 (16.7) | 5 (41.7) | 0.600 |
Carbapenems | 6 (100.0) | 11 (91.7) | 1.000 |
Fluoroquinolones | 1 (16.7) | 8 (66.7) | 0.131 |
Glycopeptides | 2 (33.3) | 7 (58.3) | 0.620 |
Tigecycline | 2 (33.3) | 6 (50.0) | 0.638 |
Oxazolidones | 1 (16.7) | 5 (41.7) | 0.600 |
Aminoglycosides | 0 (0.0) | 3 (25.0) | 0.515 |
β-lactam/β-lactamase inhibitors | 4 (66.7) | 8 (66.7) | 1.000 |
Macrolides | 0 (0.0) | 2 (16.7) | 0.529 |
Antiviral agents | 1 (16.7) | 6 (50.0) | 0.316 |
CRE isolates | Â | Â | Â |
Klebsiella pneumoniae | 5 (83.3) | 5 (41.7) | 0.240 |
Escherichia coli | 1 (16.7) | 5 (41.7) | 0.596 |
Enterobacter cloacae | 0 (0.0) | 1 (8.3) | 0.480 |
others | 0 (0.0) | 1 (8.3) | 0.480 |
Type of hematological malignancy | Â | Â | Â |
AML | 1 (16.7) | 7 (58.3) | 0.240 |
ALL | 2 (33.3) | 4 (33.3) | 1.000 |
Lymphoma | 3 (50.0) | 1 (8.3) | 0.161 |
Antimicrobial susceptibility profiles | Â | Â | Â |
Resistant to all the tested antimicrobial agents | 0 (0.0) | 1 (8.3) | 1.000 |
Resistant to amikacin | 6 (100.0) | 10 (83.3) | 0.529 |
Resistant to tigecyclin | 6 (100.0) | 10 (83.3) | 1.000 |
Resistant to colistin | 0 (0.0) | 1 (8.3) | 0.529 |
Antimicrobial treatment | Â | Â | Â |
Carbapenems + amikacin | 1 (16.7) | 5 (41.7) | 0.600 |
Carbapenems + tigecyclin | 3 (50.0) | 6 (50.0) | 1.000 |
Carbapenems + colistin | 1 (16.7) | 2 (16.7) | 1.000 |
Carbapenems + amikacin + tigecyclin | 3 (50.0) | 4 (33.3) | 1.000 |
Carbapenems + tigecyclin + colistin | 3 (50.0) | 4 (33.3) | 0.627 |
Carbapenems + amikacin + tigecyclin + colistin | 1 (8.3) | 0(0.0) | 1.000 |